Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Contineum Therapeutics Q2 EPS $(0.62) Misses $(0.31) Estimate

Author: Benzinga Newsdesk | August 05, 2025 03:34pm
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.31) by 100 percent. This is a 58.97 percent decrease over losses of $(0.39) per share from the same period last year.

Posted In: CTNM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist